Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Firefly Neuroscience (AIFF) over the last 15 years, with Q3 2025 value amounting to $4.3 million.

  • Firefly Neuroscience's Cash & Equivalents rose 25162.6% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 25162.6%. This contributed to the annual value of $1.8 million for FY2024, which is 1553.9% down from last year.
  • Per Firefly Neuroscience's latest filing, its Cash & Equivalents stood at $4.3 million for Q3 2025, which was up 25162.6% from $5.9 million recorded in Q2 2025.
  • In the past 5 years, Firefly Neuroscience's Cash & Equivalents ranged from a high of $9.5 million in Q1 2025 and a low of $58000.0 during Q4 2022
  • Over the past 5 years, Firefly Neuroscience's median Cash & Equivalents value was $1.6 million (recorded in 2021), while the average stood at $2.5 million.
  • In the last 5 years, Firefly Neuroscience's Cash & Equivalents tumbled by 9882.38% in 2022 and then soared by 359482.76% in 2023.
  • Firefly Neuroscience's Cash & Equivalents (Quarter) stood at $4.9 million in 2021, then plummeted by 98.82% to $58000.0 in 2022, then surged by 3594.83% to $2.1 million in 2023, then dropped by 15.54% to $1.8 million in 2024, then soared by 138.95% to $4.3 million in 2025.
  • Its Cash & Equivalents was $4.3 million in Q3 2025, compared to $5.9 million in Q2 2025 and $9.5 million in Q1 2025.